Prospective clinical trials are needed to validate the impact of CHD1 deletion on response to castration, abiraterone, enzalutamide, and other antiandrogen drugs in both hormone-sensitive and -resistant prostate cancers. This evidence concerns the gene CHD1 and prostate carcinoma.